Positioning no disclosures inside 60 days, left as found
Options put/call open interest 0.47, read 2026-10-24
Ethical does not pass the values gate
Price274.08 USD
Fair value388.56
Ethical score10.0/100
RatingAVOID
Our investment reviews on this name
2026-10-22Read Accumulation272.00+0.8% to today ✓Markdown gives way to Accumulation after a 9% slide in 7 weeks
2026-08-31Read Markdown298.20-8.1% to today ✓Distribution gives way to Markdown with volume flow in agreement
2026-07-02Read Distribution293.04-6.5% to today ✓First review on file: Distribution
Our analytic regime reads on this name, dated and marked against the screened price. Small sample per name, and separate from the daily-framework accuracy on the Track Record page.
Huntington Ingalls Industries holds its Accumulation at $274.08. Consolidating, no directional conviction, held for 38 days.
As held on the ledger · 2026-10-23
Phase
Accumulation
Quantitative state
Consolidating, no directional conviction, held for 38 days
Price at the screen
$274.08
Valuation
16.21 trailing · 12.95 forward price to earnings
Values screen
FAIL· score 10.0
Beta
0.21
The Workings
Five Screens, Shown in Full
Does not pass. Business activity screen
Test
Figure
Limit
What it means
Status
Business activity
Excluded
Core business clean
Business activity: Aerospace & Defense
Fail
Five checks adapted from AAOIFI screening standards: business activity plus four balance-sheet ratios. All five must pass for ethical clearance. Every figure is arithmetic on public accounts, not judgement.
The Ethical Read
Why It Falls Short, in Plain English
Huntington Ingalls Industries does not clear the screen at the business-activity stage. It operates in aerospace and defense, so the financial ratios are not the deciding factor here.
Read as at 2026-10-28. It updates when the underlying figures move, and past reads are kept below.
Follow this verdict
Get an email when HII's ethical verdict changes
Today HII does not pass the screen. If new figures move it to a pass, we send you one short email with the before and after. Verdicts change rarely, so you may not hear from us for a long time.
Free, no account needed. Every email has a link to stop.
What the Numbers Say It Is Worth
The Fair Value Range
Our analysis reads AVOID: it trades at roughly a 42% discount to our $388.56 fair value, weak competitive moat, 10.90% revenue growth.
Fair value range in USD, drawn from the 2026-10-23 screen. The gold marker is the market price at the same screen. A 41.8% margin of safety to the base estimate.
Third-party analyst targets: 12 covering, consensus Buy. The average target sits +30% from the screen price.
Reading the gap · Both our model and the analysts see meaningful upside from here.
Price History & Projections
Where it has been, where the models see it going. History from market close data; projection points are our fair-value estimates and third-party analyst targets, dated to the 2026-10-23 screen.
Fair value and rating are our own model estimates; the Street's range reflects third-party analyst estimates. Analysis, not advice.
The Business, in Plain Words
Warship Builder Trips Hard Ethical Screen
Every time Congress votes through another carrier or destroyer, the work lands at Huntington Ingalls. The company turns those budgets into steel hulls and combat systems, yet the ethical screen rules it out on business activity grounds alone.
We pass for the same reason we passed on other defence names that clear the numbers test. Revenue is growing 13 percent, the forward multiple sits at 13.3 times, and margins are thin at 5 percent with a weak moat. None of that matters once the screen lights up red.
The 12 percent return on equity and buy-rated analyst targets do not change the call. This screen exists to keep certain exposures off the desk, full stop. Analysis, not advice.
The risks · The main risks here are ordinary market swings and the chance our fair-value read proves too optimistic.
Plain-English interpretation of our own screen data. Analysis, not advice.
Where & How to Trade
HII trades on a US exchange. As a listed security it is accessible through almost any international broker offering its home market. New to this, or investing from abroad? Our guide to accessing global markets covers brokers, currencies and the practical steps.
The Dated Journal · Newest First, Never Edited
Every Entry, As Written
2026-10-29Accumulation$274.08+0.8%Entry 15
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved up 0.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it buy, with a mean price target of $388. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-28Accumulation$272.00+0.0%Entry 14
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it buy, with a mean price target of $388. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-27Accumulation$272.00+0.0%Entry 13
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it buy, with a mean price target of $388. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-26Accumulation$272.00+0.0%Entry 12
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it B, carrying a low risk profile. Technically it is momentum reading neutral. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it buy, with a mean price target of $388. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-25Accumulation$272.00+0.0%Entry 11
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it buy, with a mean price target of $388. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-24Accumulation$272.00+0.0%Entry 10
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it buy, with a mean price target of $388. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-23Accumulation$272.00+0.0%Entry 9
The analysis reads accumulation. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it buy, with a mean price target of $388. It reported earnings in this window, a natural checkpoint for the thesis.
The framework has shifted from markdown to accumulation since the last review. Smart money appears to be quietly building positions. This typically precedes a markup phase. Price has moved down 0.0% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it D, carrying a low risk profile. Technically it is momentum reading bullish. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it buy, with a mean price target of $388. It reported earnings in this window, a natural checkpoint for the thesis.
2026-10-18Markdown$272.00+4.8%Entry 7
The analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved up 4.8% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it buy, with a mean price target of $388.
2026-10-02Markdown$259.64-12.9%Entry 6
Our analysis reads markdown. Price is trending lower. Sellers are in control and the prior trend has reversed. Price has moved down 12.9% since our last review. Ethical screening: FAIL. This security does not pass our values-based screening criteria. The risk-adjusted return profile shows modest positive risk-adjusted returns. Our composite framework grades it C, carrying a low risk profile. Technically it is holding around 6% above its long-term trend line with momentum reading neutral. Over the past year the shares are up 32%. Our forward projection puts the odds of a 10% gain over the next month near 28%. The street (11 analysts) rates it buy, with a mean price target of $388.
Each entry above was written on its date, before the outcome. A journal you can prune is not a journal.
